Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trialSabino De Placido, Edoardo Biondi, Alessio Aligi Cogoni et al.|The Lancet Oncology|2018Cited by 88
Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.Francesco Perrone, Ciro Gallo, Giancarlo Bisagni et al.|Journal of Clinical Oncology|2017Cited by 4
RAS/BRAF testing of circulating cell-free DNA (cfDNA) in RAS/BRAF wild-type (RAS/BRAF <sup>WT</sup> ) metastatic colorectal cancer (mCRC) patients: Preliminary results of the phase III LIBImAb study.Anna Maria Rachiglio, Carmine Pinto, Angela Damato et al.|Journal of Clinical Oncology|2025Cited by 1
Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E) or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer. The FATA-GIM3 trialSabino De Placido, Francesco Perrone, Ciro Gallo et al.|Annals of Oncology|2017Cited by 0
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left-sided RAS/BRAF wild-type metastatic colorectal cancer: the IMPROVE-2 trialAntonio Avallone, Umberto Malapelle, Alfonso De Stefano et al.|Research Square|2025Cited by 0